About: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
Creator	Iwata-Yoshikawa, Naoko Garron, Tania Newman, Patrick Sbrana, Elena Tseng, Chien-Te Atmar, Robert Couch, Robert Peters, Clarence
Source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory syndrome (SARS) emerged in China in 2002 and spread to other countries before brought under control. Because of a concern for reemergence or a deliberate release of the SARS coronavirus, vaccine development was initiated. Evaluations of an inactivated whole virus vaccine in ferrets and nonhuman primates and a virus-like-particle vaccine in mice induced protection against infection but challenged animals exhibited an immunopathologic-type lung disease. DESIGN: Four candidate vaccines for humans with or without alum adjuvant were evaluated in a mouse model of SARS, a VLP vaccine, the vaccine given to ferrets and NHP, another whole virus vaccine and an rDNA-produced S protein. Balb/c or C57BL/6 mice were vaccinated IM on day 0 and 28 and sacrificed for serum antibody measurements or challenged with live virus on day 56. On day 58, challenged mice were sacrificed and lungs obtained for virus and histopathology. RESULTS: All vaccines induced serum neutralizing antibody with increasing dosages and/or alum significantly increasing responses. Significant reductions of SARS-CoV two days after challenge was seen for all vaccines and prior live SARS-CoV. All mice exhibited histopathologic changes in lungs two days after challenge including all animals vaccinated (Balb/C and C57BL/6) or given live virus, influenza vaccine, or PBS suggesting infection occurred in all. Histopathology seen in animals given one of the SARS-CoV vaccines was uniformly a Th2-type immunopathology with prominent eosinophil infiltration, confirmed with special eosinophil stains. The pathologic changes seen in all control groups lacked the eosinophil prominence. CONCLUSIONS: These SARS-CoV vaccines all induced antibody and protection against infection with SARS-CoV. However, challenge of mice given any of the vaccines led to occurrence of Th2-type immunopathology suggesting hypersensitivity to SARS-CoV components was induced. Caution in proceeding to application of a SARS-CoV vaccine in humans is indicated.
has issue date	2012-04-20(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0035421
bibo:pmid	22536382
has license	cc-by
sha1sum (hex)	962c58e6dc9c1ea550eb51ce70b0d7c83dc7eff6
schema:url	https://doi.org/10.1371/journal.pone.0035421
resource representing a document's title	Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
has PubMed Central identifier	PMC3335060
has PubMed identifier	22536382
schema:publication	PLoS One
resource representing a document's body	covid:962c58e6dc9c1ea550eb51ce70b0d7c83dc7eff6#body_text
is schema:about of	named entity 'vaccine' named entity 'Because' named entity 'induced' named entity 'SARS VIRUS' named entity 'VIRUS VACCINE' named entity 'SARS CORONAVIRUS' named entity 'BUT' named entity 'PROTECTION' named entity 'LUNG DISEASE' named entity 'FERRETS' named entity 'UNDER CONTROL' named entity 'SPREAD' named entity 'EVALUATIONS' named entity 'PARTICLE' named entity 'BACKGROUND' named entity 'RELEASE' named entity 'SARS CORONAVIRUS' named entity 'CHALLENGE' named entity 'INFECTION' named entity 'NONHUMAN PRIMATES' named entity 'MICE' named entity 'COUNTRIES' named entity 'BROUGHT' named entity 'VACCINES' named entity 'INDUCED' named entity 'IMMUNIZATION' named entity 'IMMUNOPATHOLOGY' named entity 'LEADS' named entity 'PULMONARY' named entity 'CONCERN' named entity 'VACCINE DEVELOPMENT' named entity 'INACTIVATED' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'VACCINE' named entity 'ANIMALS' named entity 'CHINA' covid:arg/962c58e6dc9c1ea550eb51ce70b0d7c83dc7eff6 named entity 'vaccine' named entity 'SARS Coronavirus' named entity 'Pulmonary' named entity 'mice' named entity 'vaccine' named entity 'SARS coronavirus' named entity 'virus' named entity 'protein' named entity 'Mayo Clinic' named entity 'immunopathologic' named entity 'vaccine' named entity 'Th2' named entity 'animal models' named entity 'hypersensitivity' named entity 'vaccine' named entity 'virus' named entity 'alum' named entity 'edema' named entity 'neutralizing antibodies' named entity 'desquamation' named entity 'alum' named entity 'monocytes' named entity 'serum' named entity 'RSV' named entity 'vaccine' named entity 'Th2' named entity 'epidemiologic' named entity 'virus' named entity 'immunization' named entity 'hypersensitivity' named entity 'hypersensitivity' named entity 'virus' named entity 'complement activation' named entity 'Neutralizing antibody' named entity 'inactivated vaccine' named entity 'PBS' named entity 'vaccine'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software